Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (231-240 of 387) with videos related to

Pageof 39
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2020
Real-world persistence with dupilumab among adults with atopic dermatitisJonathan I Silverberg, Emma Guttman-Yassky, Abhijit Gadkari, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
The British Journal of Dermatology|June 3, 2022
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomesYael Renert-Yuval, Joel Correa da Rosa, Sandra Garcet, et al.
The Journal of Allergy and Clinical Immunology|December 9, 2014
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJennifer D Hamilton, Mayte Suárez-Fariñas, Nikhil Dhingra, et al.
Scientific Reports|May 31, 2018
Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteinsPatrick M Brunner, Mayte Suárez-Fariñas, Helen He, et al.
Allergy|April 2, 2024
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 yearsEmma Guttman-Yassky, Kenji Kabashima, Delphine Staumont-Salle, et al.
The Journal of Infectious Diseases|May 15, 2004
Familial clustering of classic Kaposi sarcomaEmma Guttman-Yassky, Adina Cohen, Zippi Kra-Oz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 18, 2018
Atopic dermatitis in African American patients is TRiana D Sanyal, Ana B Pavel, Jacob Glickman, et al.
Pageof 39

Showing results (231-240 of 387) with videos related to

Sort By:
Pageof 39
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2020
Real-world persistence with dupilumab among adults with atopic dermatitisJonathan I Silverberg, Emma Guttman-Yassky, Abhijit Gadkari, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Journal of the American Academy of Dermatology|December 29, 2024
The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trialsEmma Guttman-Yassky, David Rosmarin, Marjolein de Bruin-Weller, et al.
Experimental Dermatology|September 20, 2024
Efficacy and safety of ritlecitinib in vitiligo patients across Fitzpatrick skin types with biomarker analysesElena Peeva, Yuji Yamaguchi, Zhan Ye, et al.
The British Journal of Dermatology|June 3, 2022
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomesYael Renert-Yuval, Joel Correa da Rosa, Sandra Garcet, et al.
The Journal of Allergy and Clinical Immunology|December 9, 2014
Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJennifer D Hamilton, Mayte Suárez-Fariñas, Nikhil Dhingra, et al.
Scientific Reports|May 31, 2018
Author Correction: The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteinsPatrick M Brunner, Mayte Suárez-Fariñas, Helen He, et al.
Allergy|April 2, 2024
Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 yearsEmma Guttman-Yassky, Kenji Kabashima, Delphine Staumont-Salle, et al.
The Journal of Infectious Diseases|May 15, 2004
Familial clustering of classic Kaposi sarcomaEmma Guttman-Yassky, Adina Cohen, Zippi Kra-Oz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|September 18, 2018
Atopic dermatitis in African American patients is TRiana D Sanyal, Ana B Pavel, Jacob Glickman, et al.
Pageof 39